Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Semaglutide Effect on Energy Intake in Obesity
NCT02079870Phase 1Completed
- Sponsor
- Novo Nordisk
- Start
- Mar 2014
- Primary completion
- Jan 2015
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of semaglutide in obesity (2 arms), sponsored by Novo Nordisk. Primary endpoint: Ad libitum energy intake during a lunch meal at 12 weeks. Started Mar 2014; status: completed.
02
Drugs
03
Conditions
obesity
Beyond the preview
Go deeper on NCT02079870.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02079870.